Drug clinical comprehensive evaluation of tetrandrine in the treatment of pneumoconiosis.
10.3760/cma.j.cn121094-20220829-00430
- Author:
Zhi Ling ZHANG
1
;
Na HE
1
;
Xiao Han XU
1
;
Peng MEN
1
;
Li GUAN
2
;
De Hong LI
3
;
Suo Di ZHAI
1
Author Information
1. Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China.
2. Department of Occupational Disease, Peking University Third Hospital, Beijing 100191, China.
3. National Institute for Occupational Health and Poison Control, Chinese Center for Disease Control and Prevention, Beijing 100050, China.
- Publication Type:Journal Article
- Keywords:
Drug clinical comprehensive evaluation;
Drug evaluation;
Pneumoconiosis;
Safety;
Tetrandrine;
Validation studies
- MeSH:
Humans;
Pneumoconiosis/drug therapy*;
Benzylisoquinolines/therapeutic use*;
Drugs, Chinese Herbal;
Case-Control Studies
- From:
Chinese Journal of Industrial Hygiene and Occupational Diseases
2023;41(3):217-221
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the safety, effectiveness, economics, innovation, suitability and accessibility of tetrandrine in the treatment of pneumoconiosis, and provide evidence-based basis for health policy decision-making and clinical practice. Methods: In July 2022, the system searched PubMed, Embase, the Cochrane Library, CNKI, Wanfang, SinoMed databases (the retrieval time was from the establishment of the database to June 30, 2022), screened the documents that meet the standards, extracted and evaluated the data, and used the "HTA checklist" developed by the International Network of Agencies for Health Technology Assessment (INAHTA) to evaluate the HTA report. AMSTAR-2 Scale was used to evaluate the quality of systematic evaluation/Meta analysis. CHEERS Scale was used to evaluate the quality of pharmacoeconomics research. The included cohort study or case-control study was evaluated with the Newcastle-Ottawa Scale. The included randomized controlled trial (RCT) studies were evaluated using the Cochrane Risk Bias Assessment Tool (Cochrane RCT) quality evaluation criteria. Comprehensive comparison and analysis based on the characteristics of the data included in the study. Results: A total of 882 related literatures were detected from the initial screening. According to relevant standards, 8 RCT studies were finally selected for analysis. Statistical results showed that basic treatment with tetrandrine could better improve FEV(1) (MD=0.13, 95%CI: 0.06-0.20, P<0.001), FEV(1)/FVC (MD=4.48, 95%CI: 0.61-8.35, P=0.02) and clinical treatment efficiency. Tetrandrine had a low incidence of adverse reactions. The affordability coefficient of tetrandrine tablets was 0.295-0.492. Conclusion: Tetrandrine can improve the clinical symptoms and pulmonary ventilation function of pneumoconiosis patients, most of the adverse reactions are mild, and the clinical application is safe.
